(Q24198059)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24043371%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

title

Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24043371%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24043371%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

Marissa M Alejandria

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24043371%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Leonila F Dans

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24043371%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Jacinto Blas Mantaring

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24043371%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

publication date

16 September 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24043371%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

21 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24043371%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24043371%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

CD001090

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24043371%20AND%20SRC:MED&resulttype=core&format=json

Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

21 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Treatment of Neonatal Sepsis with Intravenous Immune Globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Treatment of septic thrombocytopenia with immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis: another point of view

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Pepsin-Treated Human Gamma Globulin in Bacterial Infections: A Randomized Study in Patients with Septicaemia and Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis [ISRCTN28863830].

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Intravenous immune globulin therapy for early-onset sepsis in premature neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Effect on neutrophil kinetics and serum opsonic capacity of intravenous administration of immune globulin to neonates with clinical signs of early-onset sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Intravenous polyclonal immunoglobulin administration to sepsis syndrome patients: a prospective study in a pediatric intensive care unit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Intravenous immunoglobulin in the treatment of Salmonella typhimurium infections in preterm neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Safety of intravenous immunoglobulin infusion in neonates at risk for sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Antibody to lipoid A in the treatment of septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Administration of intravenous immunoglobulins for prophylaxis or treatment of infection in preterm infants: meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Impact of immunomodulating therapy on morbidity in patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Sepsis therapy trials. Continued disappointment or reason for hope?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Improving clinical trials in the critically ill: unique challenge--sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

A critical evaluation of new agents for the treatment of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Large trials vs meta-analysis of smaller trials: how do their results compare?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Intravenous Immunoglobulin Adjunctive Therapy in Sepsis, with Special Emphasis on Severe Invasive Group A Streptococcal Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Sepsis and polyspecific intravenous immunoglobulins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Adverse effects of intravenous immunoglobulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Intravenous immunoglobulin for suspected or proven infection in neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Management of severe sepsis in patients admitted to Asian intensive care units: prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Early goal-directed therapy in the treatment of severe sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

The microbiology and outcome of sepsis in Victoria, Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Intravenous immunoglobulin for treating sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Predictive ability of meta-analyses of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090.PUB2

Multicenter randomized placebo controlled trial of therapy with intravenous immunoglobulin in decreasing mortality due to neonatal sepsis

21 January 2018

1 reference

12 December 2020

E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators

1 reference

12 December 2020

Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group

1 reference

12 December 2020

Pathophysiology of septic shock and multiple organ dysfunction syndrome and various therapeutic approaches with special emphasis on immunoglobulins

1 reference

12 December 2020

Intravenous immunoglobulin in the treatment of neonatal septicemia

1 reference

12 December 2020

Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected, serious, gram-negative sepsis

1 reference

12 December 2020

Epidemiology and outcome of sepsis in a tertiary-care hospital in a developing country

1 reference

12 December 2020

Exchange transfusion or intravenous immunoglobulin therapy as an adjunct to antibiotics for neonatal sepsis in developing countries: a pilot study

1 reference

12 December 2020

IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial

1 reference

12 December 2020

Meta-analysis: Intravenous Immunoglobulin in Critically Ill Adult Patients with Sepsis

1 reference

12 December 2020

Randomized trial of granulocyte transfusions versus intravenous immune globulin therapy for neonatal neutropenia and sepsis

1 reference

12 December 2020

Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study

1 reference

12 December 2020

A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group

1 reference

12 December 2020

Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial.

1 reference

12 December 2020

The INIS Study. International Neonatal Immunotherapy Study: non-specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo controlled, multicentre randomised trial

1 reference

12 December 2020

[Immunoglobulin therapy of postoperative sepsis]

1 reference

12 December 2020

The effects of adjuvant immunoglobulin M-enriched immunoglobulin therapy on mortality rate and renal function in sepsis-induced multiple organ dysfunction syndrome: retrospective analysis of intensive care unit patients

1 reference

12 December 2020

Plasma tumor necrosis factor levels in patients with presumed sepsis. Results in those treated with antilipid A antibody vs placebo

1 reference

12 December 2020

Treatment of Gram-Negative Septic Shock with Human IgG Antibody to Escherichia coli J5: A Prospective, Double-Blind, Randomized Trial

1 reference

12 December 2020

IgM-enriched intravenous immunoglobulin therapy in neonatal sepsis

1 reference

12 December 2020

Intravenous immunoglobulins in association with antibiotics: a therapeutic trial in septic intensive care unit patients

1 reference

12 December 2020

Immunoglobulin therapy in patients with endotoxemia and postoperative sepsis--a prospective randomized study

1 reference

12 December 2020

Cooperative Group of Additional Immunoglobulin Therapy in Severe Bacterial Infections: results of a multicenter randomized controlled trial in cases of diffuse fibrinopurulent peritonitis

1 reference

12 December 2020

[Effect of adjuvant immunoglobulin therapy on infections in patients in an surgical intensive care unit. Results of a randomized controlled study]

1 reference

12 December 2020

Immunoglobulin supplementation in prevention or treatment of neonatal sepsis

1 reference

12 December 2020

Anti-endotoxin in the treatment of severe surgical septic shock. Results of a randomized double-blind trial

1 reference

12 December 2020

A clinical trial of SM-4300 against severe infections in surgery

1 reference

12 December 2020

Clinical study on SM-4300 in the field of internal medicine

1 reference

12 December 2020

Clinical studies on the effectiveness of SM-4300, a new non-modified gammaglobulin preparation suitable for intravenous use, in refractory infections

1 reference

12 December 2020

Anti-lipopolysaccharide immunotherapy in management of septic shock of obstetric and gynaecological origin

1 reference

12 December 2020

Functional Antibacterial Activity of a Human Intravenous Immunoglobulin Preparation: in vitro and in vivo Studies

1 reference

12 December 2020

Immunoglobulin substitution in the treatment of neonatal septicemia

1 reference

12 December 2020

Comparison of two types of intravenous immunoglobulins in the treatment of neonatal sepsis

1 reference

12 December 2020

Prophylactic anti-lipopolysaccharide freeze-dried plasma in major burns: a double blind controlled trial

1 reference

12 December 2020

CDP571, a humanized antibody to human tumor necrosis factor-alpha

1 reference

12 December 2020

A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group

1 reference

12 December 2020

The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study

1 reference

12 December 2020

Round table conference on clinical trials for the treatment of sepsis

1 reference

12 December 2020

An evaluation of the hemodynamic effects of HA-1A human monoclonal antibody

1 reference

12 December 2020

Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial

1 reference

12 December 2020

The use of IgM-enriched intravenous immunoglobulin for the treatment of neonatal sepsis in preterm infants.

1 reference

12 December 2020

Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group

1 reference

12 December 2020

Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial

1 reference

12 December 2020

Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group

1 reference

12 December 2020

Supplemental immune globulins in sepsis: a critical appraisal.

1 reference

12 December 2020

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group

1 reference

12 December 2020

[The therapy of gram-negative septicotoxic diseases with pentaglobin, an immunoglobulin with an elevated IgM content (a prospective, randomized clinical study)]

1 reference

12 December 2020

Intravenous immunoglobulin in the treatment of full-term and premature newborns with sepsis

1 reference

12 December 2020

Comparison of early IgM-enriched immunoglobulin vs polyvalent IgG administration in score-identified postcardiac surgical patients at high risk for sepsis

1 reference

12 December 2020

Meta-analyses of the effectiveness of intravenous immune globulin for prevention and treatment of neonatal sepsis

1 reference

12 December 2020

Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment

1 reference

12 December 2020

Meningococcal septic shock in children: clinical and laboratory features, outcome, and development of a prognostic score

1 reference

12 December 2020

High doses of immunoglobulins decrease mortality rate of surgical patients with severe intraabdominal infections and sepsis.

1 reference

12 December 2020

The significance of immunoglobulins in the treatment of patients with sepsis and septic shock.

1 reference

12 December 2020

Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group

1 reference

12 December 2020

Use of antistaphylococcal plasma and antistaphylococcal immunoglobulin in treatment of staphylococcal sepsis

1 reference

12 December 2020

10.1002/14651858.CD001090.PUB2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24043371%20AND%20SRC:MED&resulttype=core&format=json

release_h32lfw5wvbanrk4dp2pvjovag4

21 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/h32lfw5wvbanrk4dp2pvjovag4

24 November 2022

mapped directly with Wikidata item

OpenCitations bibliographic resource ID

3217364

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24043371%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

PubMed publication ID

24043371

1 reference